Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XS-02 in Advanced Solid Tumors
NCT06531486Phase 1Recruiting
- Sponsor
- Fosun Pharma
- Start
- Aug 2024
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XS-02 in solid tumor, ovarian cancer, breast cancer and 2 more, sponsored by Fosun Pharma. Primary endpoints: Dose Limiting Toxicity at 31 days, Maximum tolerance dose and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
XS-02
03
Conditions
solid tumorovarian cancerbreast cancerendometrial cancer (EC)osteosarcoma (OS)
Beyond the preview
Go deeper on NCT06531486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531486.